Search Results - Richard Labotka

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients by Jaydeep K. Srimani, Paul M. Diderichsen, Michael J. Hanley, Karthik Venkatakrishnan, Richard Labotka, Neeraj Gupta

    Get full text
    Article


  2. 2

    Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone by Yuki Otani, Yunqi Zhao, Guanyu Wang, Richard Labotka, Mark Rogge, Neeraj Gupta, Majid Vakilynejad, Dean Bottino, Yusuke Tanigawara

    Get full text
    Article


  3. 3

    Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethaso... by Karthik Ramasamy, Nizar J. Bahlis, Shaji K. Kumar, Arun Kumar, Holly Cranmer, Bingxia Wang, Jonathan Dabora, Richard Labotka, Paul G. Richardson, Philippe Moreau

    Published in Haematologica (2024-02-01)
    Get full text
    Article


  4. 4

    Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial... by Andrew Spencer, Olga Samoilova, Wee‐Joo Chng, Richard Labotka, Cong Li, Kwang‐Wei Wu, Nakul Saxena, Xu Yan, Jae Hoon Lee, Meral Beksac

    Published in eJHaem (2022-11-01)
    Get full text
    Article


  5. 5

    A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma by Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji K. Kumar, Philip Twumasi-Ankrah, Miguel Villarreal, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar

    Published in Blood Cancer Journal (2023-01-01)
    Get full text
    Article


  6. 6

    Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial by Paul G. Richardson, Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung‐Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi‐Ankrah, Richard Labotka, Robert M. Rifkin, Sagar Lonial, Shaji K. Kumar, S. Vincent Rajkumar, Philippe Moreau

    Published in eJHaem (2023-11-01)
    Get full text
    Article


Search Tools: